Van der Meijden A P, Hall R R, Macaluso M P, Pawinsky A, Sylvester R, Van Glabbeke M
Department of Urology Bosch Medicentrum, 's-Hertogenbosch, The Netherlands.
Eur Urol. 1996;29(2):199-203.
To study the ablative activity of intravesical mitomycin C followed by intravesical bacillus Calmette-Guérin (BCG) on a papillary marker tumour and to determine the incidence of side effects.
Thirty-five patients with multiple pTa or pT1 bladder tumours were treated with 4 instillations of mitomycin C at weekly intervals followed by 6 instillations at weekly intervals of BCG-RIVM. All visible tumours were resected before starting intravesical instillations except one marker tumour. Response was determined 2 weeks after the last instillation.
The incidence of adverse effects was similar to previously reported toxicity of either mitomycin C or BCG alone. Complete response, histologically proven, was observed in 16 of 35 patients and in 3 patients without histological confirmation. One patient showed progression.
The sequential combination of mitomycin C and BCG is an efficacious treatment. The measurement of response to a marker tumour is a safe and efficient method to test new drugs or combinations of drugs.
研究膀胱内注射丝裂霉素C后再注射卡介苗（BCG）对乳头状标记肿瘤的消融活性，并确定副作用的发生率。
35例患有多个pTa或pT1膀胱肿瘤的患者接受了每周一次共4次的丝裂霉素C膀胱灌注治疗，随后每周一次共6次的BCG-RIVM膀胱灌注治疗。除一个标记肿瘤外，所有可见肿瘤在开始膀胱内灌注前均已切除。在最后一次灌注后2周确定反应情况。
不良反应的发生率与先前单独报道的丝裂霉素C或卡介苗的毒性相似。35例患者中有16例经组织学证实完全缓解，3例未经组织学确认。1例患者病情进展。
丝裂霉素C和卡介苗的序贯联合是一种有效的治疗方法。对标记肿瘤反应的测量是测试新药或药物组合的一种安全有效的方法。
